Clinical-trial insurance brokerage

01Overview and value chain#

Markers EC: Structuring and placing clinical-trial subject-injury and liability insurance across trial jurisdictions | OECD: Biopharmaceutical clinical development | Regulator: FDA (US), EMA (EU)

Clinical-trial insurance brokerage places the coverage a sponsor is legally required to carry — or contractually obligated to provide a site under a Clinical Trial Agreement — before a study can enroll its first subject. Newline Group, a Lloyd’s-market underwriting manager based in London, runs a dedicated Clinical Trials product line offering life-of-trial policies of up to ten years’ duration, country-specific annual “all trial” policies, and bespoke multi-country or global master difference-in-conditions/difference-in-limits programs. Marsh, one of the world’s largest insurance brokers, is named among the leading placement houses for clinical-trial coverage by independent market comparisons. Howden, a UK-headquartered global broker, published a 2026 sector report on how insurance can support the UK pharma industry through its current transition, reflecting its active life-sciences practice. Gallagher’s Life Sciences practice published a dedicated whitepaper, “Mitigating Risks Through Clinical Trial Funding Insurance,” alongside a Winter 2026 market summary specifically covering pharmaceutical, biotechnology, medical-device, CRO and CMO clients. WTW (Willis Towers Watson) publishes ongoing analysis of clinical-trial insurance underwriting trends, including the growing role of trial medical-expense coverage and 2025 rate predictions for life-sciences products and professional liability.

The key directions of clinical-trial insurance brokerage are:

Subject-injury and liability placement: structuring coverage for bodily injury and medical expenses incurred by trial participants, alongside sponsor and site professional-indemnity and product-liability exposure.
Multi-jurisdiction program harmonization: placing a single master or difference-in-conditions/difference-in-limits policy that satisfies the differing statutory clinical-trial insurance requirements of every country a study runs in.
Life-of-trial and annual policy structuring: choosing between a single policy covering a trial’s full multi-year duration versus renewable annual “all trial” country-specific policies, depending on program length and portfolio size.
Site indemnification advisory: advising sponsors and research sites on the insurance and indemnification terms of the Clinical Trial Agreement or Master Services Agreement before a site signs on.

Sectoral value chain#

[Trial protocol & jurisdiction scoping] ──> [Coverage structuring & underwriter placement] ──> [Policy issuance across trial countries]
                                                                    │
                                                        (Site indemnification review)
                                                                    │
                    [Claims handling to closure] <──── [Ongoing program renewal/amendment] <─── [Subject-injury claim intake]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Protocol & jurisdiction scoping	Reviewing the trial protocol and the list of countries/sites it will run in to determine the statutory insurance requirements that apply.	In: Trial protocol, site/country list. Out: Jurisdictional coverage requirement matrix.
Coverage structuring & placement	Structuring the policy (life-of-trial vs. annual, master vs. local) and placing it with underwriters.	In: Jurisdictional coverage requirement matrix. Out: Placed insurance program.
Policy issuance across trial countries	Issuing the local policy documentation required in each jurisdiction under the master program.	In: Placed insurance program. Out: Country-specific policy documents.
Site indemnification review	Advising sponsor and site on the Clinical Trial Agreement’s insurance and indemnification terms before signing.	In: Country-specific policy documents, draft CTA/MSA. Out: Reviewed indemnification terms.
Subject-injury claim intake	Receiving and triaging a reported subject-injury or liability event during trial conduct.	In: Reported adverse/injury event. Out: Intake claim file.
Claims handling to closure	Managing the claim through investigation, negotiation and settlement or denial, and feeding lessons into program renewal.	In: Intake claim file. Out: Closed claim, renewal/amendment input.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

Clinical-trial liability placement: specialist insurance-broking practice that structures and places subject-injury, professional-indemnity and product-liability coverage for a specific clinical trial program across the jurisdictions it runs in.
Multi-country trial insurance programs: master or difference-in-conditions/difference-in-limits insurance policies that harmonize local, statutorily-required clinical-trial coverage across every country a sponsor’s trial operates in under one program.

02US#

The United States hosts two of the largest global insurance-broking houses with dedicated life-sciences practices covering clinical-trial placement.

Marsh’s placement scale, Gallagher’s dedicated Life Sciences whitepaper#

Marsh: named among the leading clinical-trial insurance placement brokers in independent market comparisons, leveraging its position as one of the world’s largest insurance brokers to place complex, cross-border trial programs.
Gallagher: its Life Sciences practice publishes dedicated clinical-trial funding insurance guidance and a recurring life-sciences insurance market summary covering pharmaceutical, biotech, medical-device, CRO and CMO clients specifically.

03CN#

China is covered qualitatively rather than by a live-screened Chinese vendor: candidate Chinese clinical-trial insurance brokers searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Multinational sponsors running trials in China typically place local statutorily-required coverage through the same global brokers’ China offices or local co-insurance partners, rather than through a distinct domestic clinical-trial-insurance specialist confirmed on this screen.

No confirmed domestic specialist; global brokers’ China offices place local statutory coverage#

Global broker China offices: multinational sponsors running China trial sites typically route the locally-required clinical-trial insurance placement through the same global brokers’ China operations rather than a distinct domestic specialist.
Domestic gap: no China-headquartered clinical-trial insurance brokerage confirmed by a live 2026 source was found during this screen.

04EU#

The European Union — via UK-headquartered brokers and Lloyd’s-market underwriters — hosts the deepest specialist clinical-trial insurance capacity, including the sector’s dedicated Lloyd’s product line.

Newline’s dedicated Lloyd’s product line, Howden’s UK life-sciences transition report, WTW’s underwriting-trend analysis#

Newline Group: a Lloyd’s-market underwriting manager running a dedicated Clinical Trials product line — life-of-trial policies up to ten years, country-specific annual “all trial” policies, and bespoke multi-country or global master difference-in-conditions/difference-in-limits programs.
Howden: published a 2026 report on how insurance can support the UK pharmaceutical and life-sciences sector through its current transition, reflecting an active dedicated life-sciences broking practice.
WTW (Willis Towers Watson): publishes ongoing analysis of clinical-trial insurance underwriting trends, including trial medical-expense coverage evolution and life-sciences product/professional-liability rate predictions.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Newline Group	🇬🇧 UK	Dedicated Clinical Trials product line (Lloyd’s)	Life-of-trial policies to 10 years, multi-country DIC/DIL	commercial
Marsh	🇺🇸 USA	Clinical-trial insurance placement	Leading global placement scale	commercial
Howden	🇬🇧 UK	Life-sciences insurance broking	UK pharma-sector transition advisory	commercial
Gallagher	🇺🇸 USA	Life Sciences practice, clinical-trial funding insurance	Dedicated whitepaper + market-summary research	commercial
WTW	🇬🇧 UK	Clinical-trial insurance underwriting analysis	Trial medical-expense coverage evolution tracking	commercial

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The clinical-trial insurance brokerage “technology stack” is less software than structuring know-how, applied through a small set of recurring policy mechanisms:

Difference-in-conditions/difference-in-limits (DIC/DIL) master programs:
- Newline’s global master programs harmonize varying local statutory minimums into one placement, avoiding a patchwork of separately negotiated local policies.
Life-of-trial vs. annual policy structuring:
- Brokers choose between a single policy spanning a trial’s full multi-year duration and renewable annual all-trial policies, trading premium certainty against flexibility as a program’s country footprint changes.
Sector-specific market-trend research feeding placement strategy:
- Gallagher and WTW both publish recurring life-sciences insurance market analysis that directly informs how a given trial program is structured and timed for placement.

07Value chains and production pipelines#

Industrial pipeline for clinical-trial insurance placement#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Protocol & jurisdiction  │ ───> │ 2. Coverage structuring &   │
│    scoping                      │      │    underwriter placement         │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Site indemnification     │ <─── │ 3. Policy issuance across   │
│    review                       │      │    trial countries               │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Subject-injury claim     │ ───> │ 6. Claims handling to       │
│    intake                       │      │    closure                       │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline for clinical-trial insurance placement

Stage 1: Protocol and jurisdiction scoping

The broker reviews the trial protocol and the list of countries and sites it will run in to determine which statutory clinical-trial insurance requirements apply.

Stage 2: Coverage structuring and underwriter placement

The broker structures the policy — life-of-trial or annual, master program or local — and places it with one or more underwriters, often via the Lloyd’s market for specialist life-sciences risk.

Stage 3: Policy issuance across trial countries

Local policy documentation required in each jurisdiction is issued under the umbrella of the master program.

Stage 4: Site indemnification review

The broker or sponsor’s risk team reviews the Clinical Trial Agreement or Master Services Agreement’s insurance and indemnification terms before a site signs.

Stage 5: Subject-injury claim intake

A reported subject-injury or liability event during trial conduct is received and triaged into a claim file.

Stage 6: Claims handling to closure

The claim is investigated, negotiated and settled or denied, with lessons feeding back into the next program renewal or amendment.

Supplier	Region & tags
Newline Group	EU
Marsh	US
Howden	EU
Gallagher	US
WTW	EU

AI Recommendation

Key directions:

Subject-injury and liability placement — structuring coverage for participant bodily injury and medical expenses alongside sponsor/site professional-indemnity and product-liability exposure.
Multi-jurisdiction program harmonization — placing a single master or difference-in-conditions/difference-in-limits policy across every country a trial runs in.
Life-of-trial and annual policy structuring — choosing full multi-year coverage versus renewable annual country-specific policies.
Site indemnification advisory — reviewing a trial site’s insurance and indemnification terms before it signs a Clinical Trial Agreement.

Regulatory:

Many countries make subject-injury insurance a statutory precondition to trial approval, not an optional risk-management choice — a trial cannot legally enroll its first participant without it in those jurisdictions.
Coverage requirements differ enough by country that a program spanning several markets genuinely needs the harmonizing structure a DIC/DIL master policy provides, rather than a patchwork of separately negotiated local policies.
Insurance and indemnification terms in the Clinical Trial Agreement are a routine point of negotiation between sponsor and site before a site will sign on.

Companies not in table: Aon was named alongside Marsh and Lockton in an independent broker comparison but returned no confirming source of its own during this screen, so it was dropped rather than tabled from the listicle mention alone.

Processing note: no Chinese-headquartered specialist cleared the confirmation bar on this screen — the China section describes how multinational sponsors route locally-required coverage through the same global brokers’ China offices rather than listing an unconfirmed domestic company.

Category boundary: this is distinct from general life-sciences product-liability insurance brokerage — the buyer here needs coverage specific to an active clinical trial program (subject injury, per-jurisdiction statutory minimums, life-of-trial duration), not ongoing commercial-product liability for an approved therapy.